非糖尿病患者的自发低血糖症:一个诊断和治疗难题
Karnika Mahendiran1, Swathy Moorthy1, Lakshmi M1
1Internal Medicine, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND.
Cureus
|August 27, 2024
概括
尼西迪奥母细胞瘤,一种罕见的内源性低血糖症的原因,可以模仿胰岛素瘤. 这一案例凸显了在非糖尿病患者中考虑尼西迪奥母细胞形成症的重要性,非糖尿病患者有无法解释的低血糖症状.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 病理学 病理学 病理学
背景情况:
- 低血糖症是一种医疗紧急情况,具有潜在的神经糖症状.
- 常见的原因包括胰岛素使用和败血症,但内源性原因需要评估.
- 无芽细胞瘤,或非胰岛素瘤胰腺原性低血糖综合征,是一种罕见的差异诊断.
研究的目的:
- 为了呈现一个尼西迪奥母细胞瘤病例.
- 突出诊断挑战,使其与胰岛素瘤区分开来.
- 强调对罕见的内源性低血糖病因的评估.
主要方法:
- 一个非糖尿病男性患有复发性低血糖症的案例介绍.
- 进行了广泛的评估,以排除胰岛素瘤.
- 尼西迪奥母细胞瘤的诊断得到证实.
主要成果:
- 患者经历了两年的头和心等症状.
- 最初的评估排除了胰岛素瘤.
- 纳西迪奥母细胞瘤被确定为潜在的原因.
结论:
- 在非糖尿病患者中,不解释性低血糖症患者应考虑纳西迪奥母细胞形成症.
- 从胰岛素瘤区分尼西迪奥母细胞瘤对于适当的管理至关重要.
- 这一案例强调了内源性低血糖症综合诊断方法的重要性.
相关概念视频
Hypoglycemia and Glucagon
218
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
218
Diabetes: Symptoms, Diagnosis, and Complications
520
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
520
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Oral Hypoglycemic Agents: Glinides
149
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
149


